'Smart' insulin delivery

Drug delivered: Insulin
Innovation: Long-term insulin support for diabetics
Research organizations: North Carolina State University, University of North Carolina at Chapel Hill, Boston Children's Hospital, MIT

Making use of nanotech's ability to control the release of treatments in a very specific way, researchers in the U.S. recently developed a network of nanoparticles that enable "smart" delivery of insulin to treat diabetes without constant injections.

The delivery platform works much like a series of tiny pancreases in the bloodstream, with each nanoparticle releasing its solid core of insulin when blood sugar levels become higher than normal. Before then, the particles remain innocuous, allowing diabetics to go as long as 10 days without a shot.

The much-sought-after technology, created by scientists from North Carolina State University, the University of North Carolina at Chapel Hill, Boston Children's Hospital and Robert Langer's lab at MIT, could be very lucrative in the huge diabetes market, and the researchers are in discussions to begin human clinical trials.

'Smart' insulin delivery
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.